Anti-angiogenic sustained release intraocular implants and related methods

• US 20070059336A1
• Filed: 02/27/2006
• Published: 03/15/2007
• Est. Priority Date: 04/30/2004
• Status: Abandoned Application

• Current Assignee: Allergan, Inc. (Canada) (Abbvie Incorporated)
• Original Assignee: Allergan, Inc. (Canada) (Abbvie Incorporated)
• Inventors: Whitcup, Scott, Malone, Thomas, Hughes, Patrick, Spada, Lon, De Vries, Gerald, Blanda, Wendy, Baciu, Peter, Edelman, Jeffrey
• Application Number:
  US11/364,687
• Publication Number:
  US 20070059336A1
• Time in Patent Office: Days
• US Class Current: 424/426
• CPC Class Codes: A61K 48/0041 the non-active part being polymeric
• CPC Class Codes: A61K 9/0051 Ocular inserts, ocular implants

Abstract

Biocompatible intraocular drug delivery systems include a anti-angiogenic therapeutic agent and a polymeric component in the form of an implant, a microparticle, a plurality of implants or microparticles, and combinations thereof. The therapeutic agent is released in a biologically active form, for example, the therapeutic agent may retain its three dimensional structure when released into an eye of a patient, or the therapeutic agent may have an altered three dimensional structure but retain its therapeutic activity. The therapeutic agent may be selected from the group consisting of anti-angiogenesis peptides, hormones and nucleic acid agents. The implants may be placed in an eye to treat or reduce the occurrence of one or more ocular conditions, such as retinal damage, including glaucoma and proliferative vitreoretinopathy among others.

Claims

1. A sustained-release intraocular drug delivery system comprising:

a therapeutic component comprising an antiangiogenic peptide component; and

a polymeric component associated with the therapeutic component to permit the therapeutic component to be released into the interior of an eye of an individual at a therapeutically effective dosage for a period of time after the drug delivery system is placed in the eye.

2. The system of claim 1, wherein the polymeric component comprises a biodegradable polymer or biodegradable copolymer, the therapeutic component being associated with the polymeric component as a plurality of biodegradable particles.

3. The system of claim 1, wherein the polymeric component comprises a biodegradable polymer or biodegradable copolymer, the therapeutic component being associated with the polymeric component as a biodegradable implant.

4. The system of claim 1, wherein the therapeutic component comprises a antiangiogenic peptide component selected from the group consisting of ranibizumab, bevacizumab, VEGF-inhibiting derivatives and fragments of these, and combinations thereof.

5. The system of claim 1 wherein the therapeutic component comprises an amino acid sequence comprising a contiguous sequence of at least 10, or at least 15, or at least 20 or at least 25 or at least 30, or at least 40 or at least 50 amino acids contained in the variable heavy sequences of FIG. 3 selected from the group consisting of A.4.6.1, F(ab)-12, and humlll.

6. The system of claim 5 in which the variable heavy sequence is comprised in F(ab)-12.

7. The system of claim 5 in which the variable heavy sequence is comprised in humlll.

8. The system of claim 1 wherein the therapeutic component comprises an amino acid sequence comprising a contiguous sequence of at least 10, or at least 15, or at least 20 or at least 25 or at least 30, or at least 40 or at least 50 amino acids contained in the variable light sequences of FIG. 3 selected from the group consisting of A.4.6.1, F(ab)-12, and humk1.

9. The system of claim 8 in which the variable heavy sequence is comprised in F(ab)-12.

10. The system of claim 5 in which the variable heavy sequence is comprised in humkl.

11. The system of claim 1 in which said therapeutic component is present in a viscous aqueous medium.

12. The system of claim 11 wherein the polymeric component comprises hyaluronic acid.

13. The system of claim 1, wherein the therapeutic component comprises a monoclonal antibody that binds vascular endothelial growth factor (VEGF) or a VEGF-binding fragment thereof.

14. The system of claim 1, wherein the polymeric component comprises a polymer selected from the group consisting of biodegradable polymers, non-biodegradable polymers, biodegradable copolymers, non-biodegradable copolymers, and combinations thereof.

15. The system of claim 1, wherein the polymeric component comprises a polymer selected from the group consisting of poly-lactic acid (PLA), poly-glycolic acid (PGA), poly-lactide-co-glycolide (PLGA), polyesters, poly(ortho ester), poly(phosphazine), poly(phosphate ester), polycaprolactones, gelatin, collagen, derivatives thereof, and combinations thereof.

16. The system of claim 1, wherein the therapeutic component and the polymeric component are associated in the form of an implant selected from the group consisting of solid implants, semisolid implants, and viscoelastic implants.

17. The system of claim 1, wherein the therapeutic component and the polymeric component are associated with each other so that the release of the therapeutic component into the eye is by a method selected from the group consisting of diffusion, erosion, dissolution, osmosis, and combinations thereof.

18. The system of claim 1, wherein the therapeutic component and the polymeric component are associated with each other so that the therapeutic component is released into the eye for a time period from about four weeks to about 16 weeks after the system is placed in the interior of the eye.

19. The system of claim 1, wherein the therapeutic component and the polymeric component are associated with each other so that the therapeutic component is released into the eye for a time period greater than one year after the system is placed in the interior of the eye.

20. The system of claim 1, wherein the therapeutic component comprises at least one additional therapeutic agent other than the non-neurotoxic macromolecule therapeutic agent.

21. The system of claim 1, further comprising an excipient component.

22. The system of claim 1, wherein the drug delivery system is in the form of an extruded composition, and the non-neurotoxic macromolecule therapeutic agent is biologically active.

23. The system of claim 1 being structured to be placed in the vitreous of the eye.

24. The system of claim 1 which is formed as at least one of a rod, a wafer, and a particle.

25. A composition comprising the system of claim 1 and a ophthalmically acceptable carrier component.

26. The system of claim 1, wherein the therapeutic component and the polymeric component are associated to release an amount of the macromolecule therapeutic agent effective in providing a concentration of the macromolecule therapeutic agent in the vitreous of the eye from about 0.2 nM to about 5 μ

M.

27. The system of claim 1, wherein the therapeutic component and the polymeric component are associated to release a therapeutically effective amount of the macromolecule at a rate from about 0.003 μ

g/day to about 5000 μ

g/day.

28. A method of improving or maintaining vision of an eye of a patient, comprising the step of placing the drug delivery system of claim 1 into the interior of an eye of an individual.

29. The method of claim 28, wherein the method is effective to treat a retinal ocular condition.

30. The method of claim 28, wherein the ocular condition includes retinal damage.

31. The method of claim 28, wherein the system is placed in the posterior segment of the eye.

32. The method of claim 28, wherein the system is placed in the eye using a trocar or a syringe.

33. The method of claim 28, wherein the drug delivery system comprises a biodegradable implant containing rapamycin, and placing the implant into the interior of the eye provides treatment of an ocular condition selected from the group consisting of uveitis, macular edema, macular degeneration, proliferative retinopathy, diabetic retinopathy, retinitis pigmentosa and gluacoma.

34. The method of claim 29, wherein the implant is placed into the eye to treat age related macular degeneration.

35. The method of claim 28, wherein the drug delivery system comprises a biodegradable implant containing an inhibitor of a vascular endothelial growth factor interaction with a vascular endothelial growth factor receptor, and placing the implant into the interior of the eye is effective to treat neovascularization of the eye.